Skip Navigation


Annals of Oncology Advance Access originally published online on September 28, 2005
Annals of Oncology 2005 16(11):1719-1721; doi:10.1093/annonc/mdi373
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/11/1719    most recent
mdi373v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chua, Y. J.
Right arrow Articles by Cunningham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chua, Y. J.
Right arrow Articles by Cunningham, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Definition of disease-free survival: this is my truth–show me yours

Y. J. Chua1, D. Sargent2 and D. Cunningham1,*

1 Department of Medicine, Royal Marsden Hospital, Surrey, UK
2 Division of Biostatistics, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA

* E-mail: david.cunningham@icr.ac.uk

The first 10% of the full text of this article appears below.

In the wake of significant advances made in the treatment of advanced colorectal cancer, progress has also been made in the adjuvant treatment of this disease, for example with oxaliplatin having been shown to add benefit to 5-flurouracil (5-FU)-based adjuvant chemotherapy in two major studies [1Go, 2Go]. These studies used two different definitions of 3-year disease-free survival (DFS) as the primary end point, and reflect the contemporary interest in different possible definitions of this outcome measure relative to its use as a surrogate for overall survival (OS), the latter traditionally regarded as the ultimate measure of treatment benefit.

DFS is appealing as a surrogate end point for several reasons. Patients receiving adjuvant treatment are those who had limited disease and had all detectable cancer removed by surgery. . . . [Full Text of this Article]

Conflict of interest


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. Mathoulin-Pelissier, S. Gourgou-Bourgade, F. Bonnetain, and A. Kramar
Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals
J. Clin. Oncol., August 1, 2008; 26(22): 3721 - 3726.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. J. A. Punt, M. Buyse, C.-H. Kohne, P. Hohenberger, R. Labianca, H. J. Schmoll, L. Pahlman, A. Sobrero, and J.-Y. Douillard
Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials
J Natl Cancer Inst, July 4, 2007; 99(13): 998 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I Chau and D Cunningham
Adjuvant therapy in colon cancer--what, when and how?
Ann. Onc., September 1, 2006; 17(9): 1347 - 1359.
[Abstract] [Full Text] [PDF]